Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jiangsu Cai Qin Technology
688182
5
Dalian Dalicap Technology
301566
CN Stock MarketDetailed Quotes
688177 Bio-Thera Solutions,
- 21.11
- -0.63-2.90%
Market Closed Apr 18 15:00 CST
8.74BMarket Cap-17.13P/E (TTM)
21.92High20.83Low26.83KlotVolume21.89Open21.74Pre Close56.81MTurnover0.65%Turnover RatioLossP/E (Static)414.08MShares35.7852wk High12.35P/B8.74BFloat Cap17.7052wk Low26.09Limit Up414.08MShs Float78.00Historical High17.39Limit Down5.01%Amplitude17.09Historical Low--Dividend TTM21.18Avg Price16.15KlotAsk--Div YieldTTM100Lot Size9.83KlotBid
Bio-Thera Solutions, News
Private Companies Are Bio-Thera Solutions, Ltd.'s (SHSE:688177) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥1.2b Last Week
Biotech: Biotech 2024 Annual Report Summary
Biotech: Biotech 2024 Annual Report
Biotech 2024 Annual Report Summary
Biotech 2024 Annual Report
Bio-Thera Solutions (688177.SH): Net loss of 0.51 billion yuan in 2024.
On April 8, Gelonghui reported that Bio-Thera Solutions (688177.SH) published its annual report for 2024, revealing revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to shareholders of the listed company was -0.51 billion yuan; basic EPS was -1.23 yuan. The main reason for the year-on-year revenue growth is the continuous increase in the sales of Guleli (Adalimumab) injection, along with the new overseas supply business for Tocilizumab injections; however, the overseas partners are still in the early stage of development, resulting in a relatively small overall increase in revenue.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Express News | Bio-Thera and DR. Reddy's Execute Exclusive Commercialization Agreement for Bat2206 and Bat2506
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Bio-Thera Solutions Obtains Acceptance of Marketing Authorization Application for Golimumab Injection
Further Weakness as Bio-Thera Solutions (SHSE:688177) Drops 4.4% This Week, Taking Five-year Losses to 61%
Biotech: Biotech 2024 Annual Results Report Announcement
Biotech 2024 Annual Results Report Announcement
Bio-Thera Solutions (688177.SH): net loss of 0.509 billion yuan for the year 2024.
On February 25, Gelonghui reported that Bio-Thera Solutions (688177.SH) disclosed its performance report for 2024. During the reporting period, the company achieved revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to the parent company was -0.509 billion yuan, and the net income attributable to the parent company after deducting non-recurring gains and losses was -0.554 billion yuan; the company's basic EPS was -1.23 yuan, and the weighted average return on net assets was -53.10%.
Bio-Thera Solutions Signs Licensing Deal With Accord Biopharma for Arthritis Injection
Bio-Thera Solutions Gets Clinical Trial Approval for Breast Cancer Treatment
The highest exceeds 0.16 billion USD! Bio-Thera Solutions' Innovative Drugs overseas authorization sees new Order again.
① As of now, Bio-Thera Solutions' Golimumab injection has completed Global Phase III clinical research and its market application has been accepted by the European EMA. ② Apart from the USA market, the exclusive licensing and commercialization rights for BAT2506 in Europe, Brazil, and the rest of the Americas have been secured by STADA and SteinCares respectively.
Express News | Accord Biopharma: Exclusive Commercialization and License Agreement With Bio-Thera Solutions for Bat2506
Express News | Bio-Thera Solutions - to Receive $21 Mln Upfront, up to $143.5 Mln in Milestones Under Agreement
Express News | Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement With Intas Pharmaceuticals for Bat2506, a Proposed Biosimilar Referencing Simponi® (Golimumab), in the United States of America
Market Insights
Discussing
Gold price hits new high! Safe havens in a turbulent market?
🎙️Discussion 1. The spot gold price has soared to a new high, with numerous institutions raising their gold price forecasts, would you be m
Riddick705
Apr 9 22:07
Dont Get Smoked!